Betül Ayşe Sin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Betül Ayşe Sin has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
- Dilsad Mungan
Department of Chest Disease, Division of Immunology and Allergy, Ankara University School of Medicine
11 shared publications - Ömür Aydın
Division of Immunology and Allergy, Department of Chest Diseases, Ankara University School of Medicine
9 shared publications - Sevim Bavbek
Division of Immunology and Allergy, Department of Chest Diseases, Ankara University School of Medicine, Ankara, Turkey
8 shared publications - Zeynep Çelebi Sözener
Department of Chest Diseases, Division of Immunology and Allergy, Ankara University School of Medicine
5 shared publications - Yavuz Selim Demirel
Division of Immunology and Allergy, Department of Chest Diseases, Ankara University Faculty of Medicine, Ankara, Türkiye
4 shared publications - Betül Özdel Öztürk
Department of Immunology and Allergic Diseases, Ankara Bilkent City Hospital, 06800 Ankara, Turkey
3 shared publications
Latest Publications
- 12 July 2026
- Published by Taylor & Francis in Immunotherapy
- p. 1-10
The long-term effectiveness of specific immunotherapy in cat allergy: a real-life study
1. Globally, respiratory allergic disorders such as asthma and rhinoconjunctivitis constitute an immense health burden. Among these, pet allergies are particularly increasing in prevalence and can ...
- 12 July 2026
- Published by Taylor & Francis in Immunotherapy
- p. 1-10
The long-term effectiveness of specific immunotherapy in cat allergy: a real-life study
1. Globally, respiratory allergic disorders such as asthma and rhinoconjunctivitis constitute an immense health burden. Among these, pet allergies are particularly increasing in prevalence and can ...
- Open Access
- 2 April 2026
- Published by SAGE Publications in Annals of Otology, Rhinology & Laryngology
- Vol. 135 (8) , 591-599
Control Status of Chronic Rhinosinusitis in Severe Asthma Patients Receiving Biologics: A Real-World Cross-Sectional Study
Objective: This study aimed to determine the prevalence, subtypes, and control status of chronic rhinosinusitis (CRS) among patients with severe asthma receiving biologic therapy in a tertiary allergy clinic. Methods: A single-center, cross-sectional observational study was conducted in adult patients with severe asthma receiving biologics for at least 6 months. CRS diagnosis and control were assessed based on European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) 2020 criteria. The Sinonasal Outcome Test-22 (SNOT-22) was also administered. Statistical analyses were performed using appropriate univariate and multivariate methods. Results: Among 148 patients with severe asthma receiving biologic therapy, 97 (65.5%) were diagnosed with comorbid CRS. Of these, 68 (45.9%) had CRS with nasal polyps (CRSwNP) and 29 (19.5%) had CRS without nasal polyps (CRSsNP). A total of 54 patients (55.6%) were treated with omalizumab and 43 (44.3%) with mepolizumab. Overall, 32.9% of patients had controlled CRS, 36.0% were partly controlled, and 30.9% were uncontrolled. In multivariable ordinal regression analysis, the presence of N-ERD and higher BMI were associated with poorer CRS control, whereas early-onset asthma and prior maintenance systemic corticosteroid use were associated with better control, suggesting that these factors may be related to CRS control status in this population. Conclusions: CRS is highly prevalent among patients with severe asthma receiving biologics, and approximately one-third remain uncontrolled despite treatment. These findings emphasize the importance of regular upper airway assessment and may inform future strategies for optimizing biologic selection and treatment outcomes in this population.
- 2 April 2026
- Published by SAGE Publications in Annals of Otology, Rhinology & Laryngology
- Vol. 135 (8) , 591-599
Open AccessControl Status of Chronic Rhinosinusitis in Severe Asthma Patients Receiving Biologics: A Real-World Cross-Sectional Study
Objective: This study aimed to determine the prevalence, subtypes, and control status of chronic rhinosinusitis (CRS) among patients with severe asthma receiving biologic therapy in a tertiary allergy clinic. Methods: A single-center, cross-sectional observational study was conducted in adult patients with severe asthma receiving biologics for at least 6 months. CRS diagnosis and control were assessed based on European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) 2020 criteria. The Sinonasal Outcome Test-22 (SNOT-22) was also administered. Statistical analyses were performed using appropriate univariate and multivariate methods. Results: Among 148 patients with severe asthma receiving biologic therapy, 97 (65.5%) were diagnosed with comorbid CRS. Of these, 68 (45.9%) had CRS with nasal polyps (CRSwNP) and 29 (19.5%) had CRS without nasal polyps (CRSsNP). A total of 54 patients (55.6%) were treated with omalizumab and 43 (44.3%) with mepolizumab. Overall, 32.9% of patients had controlled CRS, 36.0% were partly controlled, and 30.9% were uncontrolled. In multivariable ordinal regression analysis, the presence of N-ERD and higher BMI were associated with poorer CRS control, whereas early-onset asthma and prior maintenance systemic corticosteroid use were associated with better control, suggesting that these factors may be related to CRS control status in this population. Conclusions: CRS is highly prevalent among patients with severe asthma receiving biologics, and approximately one-third remain uncontrolled despite treatment. These findings emphasize the importance of regular upper airway assessment and may inform future strategies for optimizing biologic selection and treatment outcomes in this population.
- Open Access
- 12 December 2025
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 55 (6) , 1487-1496
Impact of patient education meetings on disease knowledge in chronic urticaria patients
Background/aim: Chronic urticaria (CU) is a manageable disease with symptoms of itching and visible lesions that can disrupt daily life and reduce quality of life. The severity of symptoms can vary, and the cause is often unknown. Concerns among patients as regards to treatment and prognosis highlight the need for disease education to enhance self-management and reduce anxiety. The present study examines the effect of disease education on the knowledge level of CU patients. Materials and methods: Patients with CU who presented to the allergy clinics of two tertiary university hospitals were invited to inperson education sessions including slide presentations given by faculty members. A 27-question survey was administered before and after the sessions addressing the subject matter, including definitions, causes, diagnostic tests, and treatment options for CU. Results: Included in the study were 83 patients (57 female; 26 male). The average number of correct answers prior to the education session was 13.62, and this increased to 19.48 after education. The most frequently incorrect answers were related to the importance of skin prick tests in cases of urticaria, the daily doses of antihistamines, and the use of topical corticosteroid treatment. The average number of correct answers post-education increased significantly among the university graduates, from 15.45 to 21.72 (p < 0.001), in high school graduates from 11.15 to 17.78 (p < 0.001), and in middle school graduates from 11.71 to 18.14 (p = 0.018). In contrast, the increase was not statistically significant among primary school graduates (p = 0.252). A total of 77 (92%) patients increased their scores after the education session. Conclusion: Patients can benefit from the provision of accurate and reliable information about their disease. Face-to-face education effectively increased knowledge across all educational levels in patients with CU, and reduced their reliance on unreliable online sources. This enhanced understanding is expected to lead to better treatment adherence and self-management skills.
- 12 December 2025
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 55 (6) , 1487-1496
Open AccessImpact of patient education meetings on disease knowledge in chronic urticaria patients
Background/aim: Chronic urticaria (CU) is a manageable disease with symptoms of itching and visible lesions that can disrupt daily life and reduce quality of life. The severity of symptoms can vary, and the cause is often unknown. Concerns among patients as regards to treatment and prognosis highlight the need for disease education to enhance self-management and reduce anxiety. The present study examines the effect of disease education on the knowledge level of CU patients. Materials and methods: Patients with CU who presented to the allergy clinics of two tertiary university hospitals were invited to inperson education sessions including slide presentations given by faculty members. A 27-question survey was administered before and after the sessions addressing the subject matter, including definitions, causes, diagnostic tests, and treatment options for CU. Results: Included in the study were 83 patients (57 female; 26 male). The average number of correct answers prior to the education session was 13.62, and this increased to 19.48 after education. The most frequently incorrect answers were related to the importance of skin prick tests in cases of urticaria, the daily doses of antihistamines, and the use of topical corticosteroid treatment. The average number of correct answers post-education increased significantly among the university graduates, from 15.45 to 21.72 (p < 0.001), in high school graduates from 11.15 to 17.78 (p < 0.001), and in middle school graduates from 11.71 to 18.14 (p = 0.018). In contrast, the increase was not statistically significant among primary school graduates (p = 0.252). A total of 77 (92%) patients increased their scores after the education session. Conclusion: Patients can benefit from the provision of accurate and reliable information about their disease. Face-to-face education effectively increased knowledge across all educational levels in patients with CU, and reduced their reliance on unreliable online sources. This enhanced understanding is expected to lead to better treatment adherence and self-management skills.
- 28 August 2025
- Published by Elsevier in Respiratory Medicine
- Vol. 248, 108332
Benralizumab in severe eosinophilic asthma: A real-life data from Türkiye
- 28 August 2025
- Published by Elsevier in Respiratory Medicine
- Vol. 248, 108332
Benralizumab in severe eosinophilic asthma: A real-life data from Türkiye
- Open Access
- 6 October 2023
- Published by Elsevier in World Allergy Organization Journal
- Vol. 16 (10) , 100822
Apples and pears serve the same purpose: Better diagnosis for anaphylaxis
- 6 October 2023
- Published by Elsevier in World Allergy Organization Journal
- Vol. 16 (10) , 100822
Open AccessApples and pears serve the same purpose: Better diagnosis for anaphylaxis
- 1 January 2022
- Published by Bilimsel Tip Publishing House in Tuberk Toraks
- Vol. 70 (3) , 231-241
Incidence and clinical course of COVID-19 in patients using omalizumab for chronic spontaneous urticaria and/or severe allergic asthma and using mepolizumab for severe eosinophilic asthma: A single center real life experience
Incidence and clinical course of COVID-19 in patients using omalizumab for chronic spontaneous urticaria and/or severe allergic asthma and using mepolizumab for severe eosinophilic asthma: A single center real life experienceIntroduction: To assess the incidence and course of COVID-19 in patients with severe asthma/chronic spontaneous urticaria using biological agents.Materials and Methods: A total of 202 patients (142 with asthma, and 60 with urticaria) were enrolled. The subjects were asked via face-to-face or telephone interview whether they had been diagnosed with COVID-19 and the course of the disease.Results: Study group consisted of 132 women, and 70 men (median age= 48 years). Median omalizumab dose was 300 mg/month in asthma (min-max= 150-1200 mg). The mepolizumab dose of two patients diagnosed with EGPA was 300 mg/month. Thirty one (15.3%) patients were diagnosed with COVID-19, 22 (71%) of whom were receiving omalizumab and nine (29%) were receiving mepolizumab. Asthma or chronic spontaneous urticaria diagnosis, age, sex, smoking, weight, comorbidities, atopy, and biological agent use were not statistically different between patients with or without COVID-19. Nine COVID-19 patients were hospitalized, and three of them required intensi-ve care. Mepolizumab usage was higher in hospitalized patients (5, 55.6%), whereas omalizumab usage was higher in home-treated patients (18, 81%). The mean duration of biological use in home-treated patients was significantly higher than that of the hospitalized patients (35.64 months vs. 22.56 months, p= 0.024). Biological treatment was interrupted in 47 (23%) patients, self-interruption due to the infection risk was the foremost reason (34%).Conclusion: The incidence of COVID-19 among patients with asthma and urticaria on mepolizumab and omalizumab was higher compared to studies from other countries. The disease course appeared mild in patients receiving long-term biological therapy.
- 1 January 2022
- Published by Bilimsel Tip Publishing House in Tuberk Toraks
- Vol. 70 (3) , 231-241
Incidence and clinical course of COVID-19 in patients using omalizumab for chronic spontaneous urticaria and/or severe allergic asthma and using mepolizumab for severe eosinophilic asthma: A single center real life experience
Incidence and clinical course of COVID-19 in patients using omalizumab for chronic spontaneous urticaria and/or severe allergic asthma and using mepolizumab for severe eosinophilic asthma: A single center real life experienceIntroduction: To assess the incidence and course of COVID-19 in patients with severe asthma/chronic spontaneous urticaria using biological agents.Materials and Methods: A total of 202 patients (142 with asthma, and 60 with urticaria) were enrolled. The subjects were asked via face-to-face or telephone interview whether they had been diagnosed with COVID-19 and the course of the disease.Results: Study group consisted of 132 women, and 70 men (median age= 48 years). Median omalizumab dose was 300 mg/month in asthma (min-max= 150-1200 mg). The mepolizumab dose of two patients diagnosed with EGPA was 300 mg/month. Thirty one (15.3%) patients were diagnosed with COVID-19, 22 (71%) of whom were receiving omalizumab and nine (29%) were receiving mepolizumab. Asthma or chronic spontaneous urticaria diagnosis, age, sex, smoking, weight, comorbidities, atopy, and biological agent use were not statistically different between patients with or without COVID-19. Nine COVID-19 patients were hospitalized, and three of them required intensi-ve care. Mepolizumab usage was higher in hospitalized patients (5, 55.6%), whereas omalizumab usage was higher in home-treated patients (18, 81%). The mean duration of biological use in home-treated patients was significantly higher than that of the hospitalized patients (35.64 months vs. 22.56 months, p= 0.024). Biological treatment was interrupted in 47 (23%) patients, self-interruption due to the infection risk was the foremost reason (34%).Conclusion: The incidence of COVID-19 among patients with asthma and urticaria on mepolizumab and omalizumab was higher compared to studies from other countries. The disease course appeared mild in patients receiving long-term biological therapy.
- 1 January 2022
- Published by Allergy, Asthma, and Immunology Association of Thailand in Asian Pacific Journal of Allergy and Immunology
- Vol. 41 (3) , 186-192
Field sting reactions in patients receiving Hymenoptera venom immunotherapy: real-life experience
Background: Hymenoptera stings can cause systemic allergic reactions (SARs) that are prevented by venom immunotherapy (VIT). Sting challenge tests or field stings are used to evaluate the outcome of VIT. Objective: The aim of the study was to investigate the consequences of field stings in patients during or after completion of VIT, and to identify patients at higher risk. Methods: Patients treated with VIT between 1995 and 2018 were retrospectively evaluated. Contacted patients were invited to the clinic and a questionnaire was conducted regarding the history of field stings. Results: A total of 115 patients (F/M: 45/70, mean age: 38.5 +/- 12 years) treated with VIT were included; 74/115 were contacted and asked about field stings after VIT cessation. A history of 73 field stings was reported in 38 patients, 25 of whom were treated with honeybee venom and 13 with common wasp venom. Eighteen of the reactions were SARs [8 with honeybees (1 grade-I, 6 grade-II, 1 grade-III) and 10 with common wasps (1 grade-I, 5 grade-II, 4 grade-III)]. There was no association between the severity of index reactions and field stings with either the honeybee or common wasp. The median duration of VIT was longer in patients showing no reaction than in patients with an SAR. Of the 7 patients on ACE inhibitors or beta-blockers, 1 asthmatic patient developed grade-II SAR due to field stings in the first year of VIT. Conclusion: This study confirms that VIT lasting at least 3 years is effective in preventing SARs after field stings.
- 1 January 2022
- Published by Allergy, Asthma, and Immunology Association of Thailand in Asian Pacific Journal of Allergy and Immunology
- Vol. 41 (3) , 186-192
Field sting reactions in patients receiving Hymenoptera venom immunotherapy: real-life experience
Background: Hymenoptera stings can cause systemic allergic reactions (SARs) that are prevented by venom immunotherapy (VIT). Sting challenge tests or field stings are used to evaluate the outcome of VIT. Objective: The aim of the study was to investigate the consequences of field stings in patients during or after completion of VIT, and to identify patients at higher risk. Methods: Patients treated with VIT between 1995 and 2018 were retrospectively evaluated. Contacted patients were invited to the clinic and a questionnaire was conducted regarding the history of field stings. Results: A total of 115 patients (F/M: 45/70, mean age: 38.5 +/- 12 years) treated with VIT were included; 74/115 were contacted and asked about field stings after VIT cessation. A history of 73 field stings was reported in 38 patients, 25 of whom were treated with honeybee venom and 13 with common wasp venom. Eighteen of the reactions were SARs [8 with honeybees (1 grade-I, 6 grade-II, 1 grade-III) and 10 with common wasps (1 grade-I, 5 grade-II, 4 grade-III)]. There was no association between the severity of index reactions and field stings with either the honeybee or common wasp. The median duration of VIT was longer in patients showing no reaction than in patients with an SAR. Of the 7 patients on ACE inhibitors or beta-blockers, 1 asthmatic patient developed grade-II SAR due to field stings in the first year of VIT. Conclusion: This study confirms that VIT lasting at least 3 years is effective in preventing SARs after field stings.
- Open Access
- 1 January 2022
- Published by Wolters Kluwer Health in Asia Pacific Allergy
- Vol. 12 (1) , e6
Allergen-specific immunotherapy practices and course of coronavirus disease 2019 (COVID-19) in patients during COVID-19
Erkoç M, et al. Asia Pac Allergy. 2022 Jan;12(1):e6. https://doi.org/10.5415/apallergy.2022.12.e6
- 1 January 2022
- Published by Wolters Kluwer Health in Asia Pacific Allergy
- Vol. 12 (1) , e6
Open AccessAllergen-specific immunotherapy practices and course of coronavirus disease 2019 (COVID-19) in patients during COVID-19
Erkoç M, et al. Asia Pac Allergy. 2022 Jan;12(1):e6. https://doi.org/10.5415/apallergy.2022.12.e6
- Open Access
- 1 April 2021
- Published by Wolters Kluwer Health in Asia Pacific Allergy
- Vol. 11 (2)
Coincidence of pollen season and coronavirus disease 2019 pandemic: less time outdoors - lesser allergy symptoms in 2020
Background: This year, pollen season coincided with the first wave of the coronavirus disease 2019 pandemic. Strict preventive measures have been implemented during April and May and then a normalization phase started in our country in June. Our aim is to evaluate the effect of preventive measures during the pandemic process on allergic airway disease symptoms. Methods: A prospective questionnaire-based study was planned and a questionnaire form was sent to the cell-phones of the subjects with pollen allergy followed in our clinic. Number of airborne grass pollens was determined by Burkard volumetric 7-day spore trap. Results: A total of 222 pollen allergic patients were included in the study. At the beginning of the pandemic, majority of the subjects were spending time mostly indoors. The rate of home-office workers gradually decreased and the rate of office workers and the number of days at work increased from April to June, significantly. Nasal and ocular symptoms of the patients, also increased in June compared to April and May and, approximately one-third of the patients had less symptoms when compared to the same period of the previous year. The rates of using a face mask and taking a shower on return home were high among the subjects during all season. Conclusion: Our study showed that spending less time outside during the pollen season and wearing a mask outdoors reduces exposure to pollens and causes a reduction in symptoms. Thus, strict application of measures that cannot be applied in daily practice can make a significant contribution to the management of seasonal allergic rhinitis.
- 1 April 2021
- Published by Wolters Kluwer Health in Asia Pacific Allergy
- Vol. 11 (2)
Open AccessCoincidence of pollen season and coronavirus disease 2019 pandemic: less time outdoors - lesser allergy symptoms in 2020
Background: This year, pollen season coincided with the first wave of the coronavirus disease 2019 pandemic. Strict preventive measures have been implemented during April and May and then a normalization phase started in our country in June. Our aim is to evaluate the effect of preventive measures during the pandemic process on allergic airway disease symptoms. Methods: A prospective questionnaire-based study was planned and a questionnaire form was sent to the cell-phones of the subjects with pollen allergy followed in our clinic. Number of airborne grass pollens was determined by Burkard volumetric 7-day spore trap. Results: A total of 222 pollen allergic patients were included in the study. At the beginning of the pandemic, majority of the subjects were spending time mostly indoors. The rate of home-office workers gradually decreased and the rate of office workers and the number of days at work increased from April to June, significantly. Nasal and ocular symptoms of the patients, also increased in June compared to April and May and, approximately one-third of the patients had less symptoms when compared to the same period of the previous year. The rates of using a face mask and taking a shower on return home were high among the subjects during all season. Conclusion: Our study showed that spending less time outside during the pollen season and wearing a mask outdoors reduces exposure to pollens and causes a reduction in symptoms. Thus, strict application of measures that cannot be applied in daily practice can make a significant contribution to the management of seasonal allergic rhinitis.